

HEALTH CHOICE

UTAH

PRIOR AUTHORIZATION REQUEST FORM

BENLYSTA®

For authorization, please answer each question and fax this form PLUS chart notes back to the Health Choice Utah Prior Authorization Department.

- For **Medical Pharmacy** please fax requests to: 801-646-7300
- For **Retail Pharmacy** please fax requests to: 385-425-4052

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Benlysta® (belimumab)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
SYSTEMIC LUPUS ERYTHEMATOSUS			
1. Does the member have a confirmed diagnosis of active moderate to severe systemic lupus erythematosus?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Does member meet age requirements for the requested formulation? <ul style="list-style-type: none"> • Member must be ≥5 years for intravenous administration. NOTE: Intravenous administration is non-preferred for members > 80 kg • Member must be ≥18 years for subcutaneous administration. 	<input type="checkbox"/>	<input type="checkbox"/>	
3. Is the request made by, or in consultation with, a rheumatologist?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Does the member have a Safety of Estrogen in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of ≥ 6?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Does the member have active musculoskeletal or cutaneous disease that is unresponsive to standard therapy with glucocorticoids and/or other immunosuppressive agents?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

6. Is there documentation of corticosteroid-dependent disease (prednisone equivalent dose $\geq 10\text{mg/day}$) OR trial and failure of both hydroxychloroquine AND at least 1 immunosuppressant (e.g., azathioprine, methotrexate, mycophenolate)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Has the member been at least 80% compliant for at least 6 months with their baseline therapy (i.e., steroids and/or immunosuppressants)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
8. Will Benlysta® be used concurrently with baseline therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
9. Does the member have documentation of active central nervous system lupus (e.g. generalized seizures, psychosis, stroke, peripheral neuropathies)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
10. Has the member received any other biologics, immunoglobulins, IV cyclophosphamide, or prednisone $>100\text{mg}$ daily within the last 6 months?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
LUPUS NEPHRITIS			
1. Does the member have a confirmed diagnosis of lupus nephritis?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the request made by, or in consultation with, a nephrologist or rheumatologist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Did the member have a kidney biopsy showing a histological diagnosis of lupus nephritis Class III, IV or V?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does documentation show a recent $\text{eGFR} \geq 30 \text{ mL/min/1.73m}^2$?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Has the member had dialysis in the past 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	
6. Is the member currently receiving standard immunosuppressive therapy for systemic lupus erythematosus?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Will Benlysta® be used concurrently with baseline therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
8. Does the member have active central nervous system lupus (e.g. generalized seizures, psychosis, stroke, peripheral neuropathies)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
9. Has the member received any other biologics, immunoglobulins, IV cyclophosphamide, or prednisone $>100\text{mg}$ daily within the last 6 months?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
SYSTEMIC LUPUS ERYTHEMATOSUS			
1. Is the request for reauthorization of therapy for systemic lupus erythematosus?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does clinical documentation show continued medical necessity, as well as efficacy and tolerability of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Does documentation show continued use of baseline therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
LUPUS NEPHRITIS			
1. Is the request for reauthorization of therapy for lupus nephritis?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member had an improvement in organ dysfunction, reduction in flares, reduction in corticosteroid dose, decrease of anti-dsDNA titer and/or improvement in complement levels?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Does documentation show continued use of standard therapy during Benlysta® administration?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.

Additional information:

Physician Signature:

****Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-HCU-081
Origination Date: 01/01/2022
Reviewed/Revised Date: 07/29/2024
Next Review Date: 07/29/2025
Current Effective Date: 08/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.